查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1654632

全球心房顫動市場 - 2025 至 2033 年

Global Atrial Fibrillation Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球心房顫動市場規模達到 267.5 億美元，預計到 2033 年將達到 637.9 億美元，2025-2033 年預測期內的複合年成長率為 10.6%。

心房顫動是一種心臟上腔（稱為心房）出現混亂電脈衝，導致心跳快速且不規律的疾病。這種不規律會導致心悸、頭暈、疲勞和昏厥等症狀。 AFib 在老年人和患有高血壓、糖尿病和肥胖症等潛在健康問題的人中尤其常見。

全球心房顫動市場涵蓋致力於心房顫動 (AFib) 的診斷、治療和管理的經濟部門，心房顫動是一種常見的心律不整類型，其特徵是心律不整且通常心跳過快。 AFib 可能導致嚴重的併發症，包括增加中風和心臟衰竭的風險，因此有效的治療至關重要。這些因素推動了全球心房顫動市場的擴張。

市場動態：

促進因素與約束因素

醫療科技的進步

全球心房顫動 (AFib) 市場受到醫療技術進步的極大推動，醫療技術進步徹底改變了這種常見心律不整的診斷、治療和管理。這些創新不僅改善了患者的治療效果，而且還提高了程序效率並擴大了醫療服務提供者和患者的治療選擇。

這種創新技術利用電微脈衝在心臟組織中產生針對性病變，而不是傳統的熱或冷方法。 FARAPULSE 系統的最新批准體現了 PFA 如何為 AFib 治療提​​供更精確的方法，透過有效隔離肺靜脈並最大限度地減少併發症，實現更快、更安全的手術並提高成功率。 3D 映射系統等先進映射技術的整合徹底改變了導管消融程序。這些系統提供心臟電活動的即時可視化，使電生理學家能夠準確識別和定位導致 AFib 的區域。

配備心電圖功能的智慧手錶已成為持續心律監測的寶貴工具。 Apple Watch 等裝置以及其他穿戴式裝置可以即時追蹤 AFib 發作，有助於早期診斷，而無需單純依賴傳統的心電圖 (EKG)。人工智慧擴大被用於增強消融過程中的訊號分析，幫助臨床醫生更有效地識別心律不整的觸發因素。透過分析先前 AFib 病例的複雜資料集，AI 可以幫助確定需要介入的區域，從而有可能提高治療持續性 AFib 的成功率。

此外，該行業的主要參與者推出了創新產品，將推動全球心房顫動市場的成長。例如，2024年10月，強生醫療科技在歐洲各地的醫院推出了VARIPULSE平台，代表了心房顫動(AFib)治療領域的重大創新。此創新平台採用脈衝場消融 (PFA) 技術，為藥物抵抗性陣發性心房顫動患者提供更安全、更有效的解決方案。

此外，2023 年 8 月，GE HealthCare 宣布推出用於心房顫動 (AFib) 的 CardioVisio，這是一款創新的數位工具，旨在幫助臨床醫生可視化與疾病進展相關的全面、縱向資料。這項創新工具整合了來自多個資料來源的資訊，以增強臨床決策並支持符合最新 AFib 指南的循證實踐。所有這些因素都要求全球心房顫動市場的發展。

此外，對微創手術的需求不斷成長，促進了全球心房顫動市場的擴張。

治療費用高昂

全球心房顫動 (AFib) 市場面臨重大挑戰，主要是因為治療這種常見心律不整的治療費用高昂。這些費用可能會阻止患者尋求必要的護理並給醫療保健系統帶來沉重的負擔。以下是這些高昂的治療費用如何影響 AFib 市場的解釋。

根據美國國家生物技術資訊中心 (NCBI) 2024 年 2 月的研究資料，心房顫動 (AF) 患者的增量年化費用估計為每位患者 12,789 美元 +- 161,749 美元。醫療保健成本的大幅增加主要是由幾個關鍵因素造成的，包括醫療保健就診次數的增加、與 AF 相關的不良臨床事件以及對特定 AF 相關干預措施的需求。

與沒有心房顫動的患者相比，心房顫動患者通常需要更頻繁的醫療就診。這包括住院和門診，這會導致更高的整體醫療費用。例如，患有持續性心房顫動 (PeAF) 的患者由於住院率增加和病情複雜，往往需要承擔最高的費用。因此，上述因素可能會限制全球心房顫動市場的潛在成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 醫療科技的進步
    • 限制
      • 治療費用高昂
    • 機會
    • 影響分析

第5章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT 分析
  • 未滿足的需求

第 6 章：按治療類型

  • 藥物治療
    • 抗心律不整藥物
    • 胺碘酮
    • 決奈達隆
    • 多非利特
    • 索他洛爾
    • 氟卡尼
    • 普羅帕酮
    • 地高辛
    • 抗凝血藥物
    • 華法林
    • 達比加群
    • 利伐沙班
    • 阿哌沙班
    • 依度沙班
    • 非二氫吡啶類鈣離子通道阻斷劑
    • 地爾硫卓
    • 維拉帕米
    • BETA受體阻斷劑
    • 美托洛爾
    • 卡維地洛
  • 其他
  • 非藥物治療
    • 導管消融
    • 迷宮手術
    • 電復律
    • 其他

第 7 章：按最終用戶

  • 醫院及專科診所
  • 門診手術中心
  • 其他

第 8 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第10章：公司簡介

  • AdvaCare Pharma
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Glenmark Pharmaceuticals Inc.
  • GSK plc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • DAIICHI SANKYO COMPANY, LIMITED.
  • AstraZeneca
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Medtronic
  • Abbott.

第 11 章：附錄

簡介目錄
Product Code: PH446

The global atrial fibrillation market reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033.

Atrial fibrillation is a condition in which the heart's upper chambers, known as the atria, experience chaotic electrical impulses, resulting in a fast and irregular heartbeat. This irregularity can cause symptoms such as palpitations, dizziness, fatigue, and fainting. AFib is particularly common among older adults and individuals with underlying health issues such as hypertension, diabetes, and obesity.

The global atrial fibrillation market encompasses the economic sector dedicated to the diagnosis, treatment, and management of atrial fibrillation (AFib), a prevalent type of arrhythmia characterized by irregular and often rapid heartbeats. AFib can lead to serious complications, including an increased risk of stroke and heart failure, making effective treatment essential. These factors have driven the global atrial fibrillation market expansion.

Market Dynamics: Drivers & Restraints

Advances in Medical Technology

The global atrial fibrillation (AFib) market is significantly driven by advances in medical technology, which have transformed the diagnosis, treatment, and management of this prevalent arrhythmia. These innovations not only enhance patient outcomes but also improve procedural efficiencies and expand treatment options for healthcare providers and patients alike.

This innovative technique utilizes micro pulses of electricity to create targeted lesions in cardiac tissue, as opposed to traditional heat or cold methods. The recent approval of the FARAPULSE system exemplifies how PFA provides a more precise approach to AFib treatment, leading to faster, safer procedures and improved success rates by effectively isolating the pulmonary veins and minimizing complications. The integration of advanced mapping technologies, such as 3D mapping systems, has revolutionized catheter ablation procedures. These systems offer real-time visualization of the heart's electrical activity, enabling electrophysiologists to accurately identify and target areas responsible for AFib.

Smartwatches equipped with ECG capabilities have emerged as valuable tools for continuous heart rhythm monitoring. Devices like the Apple Watch and other wearables allow for real-time tracking of AFib episodes, facilitating early diagnosis without relying solely on traditional electrocardiograms (EKGs). AI is increasingly being utilized to enhance signal analysis during ablation procedures, helping clinicians identify arrhythmia triggers more efficiently. By analyzing complex datasets from previous AFib cases, AI can assist in pinpointing areas that require intervention, potentially increasing the success rates of treating persistent AFib.

Furthermore, key players in the industry have innovative launches that would drive this global atrial fibrillation market growth. For instance, in October 2024, Johnson & Johnson MedTech introduced the VARIPULSE Platform in hospitals across Europe, representing a significant innovation in the treatment of atrial fibrillation (AFib). This innovative platform employs pulsed field ablation (PFA) technology, offering a safer and more effective solution for patients suffering from drug-refractory paroxysmal AFib.

Also, in August 2023, GE HealthCare announced the launch of CardioVisio for Atrial Fibrillation (AFib), an innovative digital tool aimed at assisting clinicians in visualizing comprehensive, longitudinal data related to disease progression. This innovative tool integrates information from multiple data sources to enhance clinical decision-making and support evidence-based practices aligned with the latest AFib guidelines. All these factors demand the global atrial fibrillation market.

Moreover, the growing demand for minimally invasive procedures contributes to the global atrial fibrillation market expansion.

High Costs of Treatment

The global atrial fibrillation (AFib) market faces significant challenges primarily due to the high costs of treatment associated with managing this common arrhythmia. These costs can deter patients from seeking necessary care and place a substantial burden on healthcare systems. Here's an explanation of how these high treatment costs impact the AFib market.

According to the National Center for Biotechnology Information (NCBI) research data in February 2024, the incremental annualized cost for patients with atrial fibrillation (AF) is estimated at $12,789 +- $161,749 per patient. This significant increase in healthcare costs is primarily driven by several key factors, including heightened rates of healthcare encounters, adverse clinical events associated with AF, and the need for specific AF-related interventions.

Patients with AF typically require more frequent healthcare visits compared to those without the condition. This includes both inpatient and outpatient visits, which lead to higher overall medical expenses. For instance, individuals with persistent atrial fibrillation (PeAF) often incur the highest costs due to increased hospitalization rates and the complexity of their condition. Thus, the above factors could be limiting the global atrial fibrillation market's potential growth.

Segment Analysis

The global atrial fibrillation market is segmented based on treatment type, end-user, and region.

Treatment Type:

The pharmacological treatment segment is expected to dominate the global atrial fibrillation market share

The pharmacological treatment segment holds a major portion of the global atrial fibrillation market share and is expected to continue to hold a significant portion of the global atrial fibrillation market share during the forecast period.

The pharmacological treatment segment for atrial fibrillation (AFib) is essential for managing this common heart condition and preventing its serious complications, particularly strokes. This segment is primarily divided into two main categories including anti-arrhythmic drugs and anticoagulant drugs. Anti-arrhythmic medications are designed to control heart rhythm and alleviate symptoms associated with AFib. They function by normalizing the heart's electrical activity or reducing the frequency of arrhythmias. These medications stabilize the heart's electrical activity by affecting ion channels involved in cardiac conduction, helping restore a normal rhythm and potentially reducing episodes of AFib.

Commonly used anti-arrhythmic drugs include amiodarone, sotalol, and flecainide. The choice of drug often depends on the patient's specific condition, including the type of AFib (paroxysmal, persistent, or permanent) and any underlying health issues.

Anticoagulants play a crucial role in preventing blood clots, which can lead to strokes-a significant risk associated with AFib. Warfarin has been the traditional anticoagulant for many years. While effective, it requires regular monitoring of blood levels (International Normalized Ratio, INR) to ensure therapeutic effectiveness and minimize the risk of bleeding. Many patients find managing warfarin challenging due to its complexity and dietary restrictions. More recently, NOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban have emerged as preferred alternatives to warfarin. These newer agents do not require routine monitoring and have fewer dietary restrictions, making them more convenient for patients.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this segment's growth in the global atrial fibrillation market. For instance, in December 2024, the FDA approved Rapiblyk (landiolol), a new medication specifically designed for the rapid management of irregular heartbeats in critically ill hospitalized patients experiencing severe supraventricular tachycardia (SVT), which includes conditions such as atrial fibrillation and atrial flutter. This approval represents a significant advancement in treatment options available for patients facing these potentially life-threatening arrhythmias. These factors have solidified the segment's position in the global atrial fibrillation market.

Geographical Analysis

North America is expected to hold a significant position in the global atrial fibrillation market share

North America holds a substantial position in the global atrial fibrillation market and is expected to hold most of the market share. The rising incidence of atrial fibrillation is a major driver of market growth. In the United States, Atrial fibrillation (AFib) is recognized as the most common form of irregular heartbeat, and it is projected that by 2030, around 12.1 million adults in the United States will be affected by this condition, with projections suggesting this number could reach 12.1 million by 2030. This escalating prevalence emphasizes the need for effective treatment options.

The aging demographic significantly contributes to the higher prevalence of AFib. As the population ages, there is an increased likelihood of developing cardiovascular conditions, leading to a greater demand for AFib treatments. Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options and attracting more patients toward specialized care. These advancements not only improve clinical outcomes but also increase patient preference for minimally invasive procedures.

Furthermore, a major number of key players' presence, well-advanced healthcare infrastructure, key initiatives & product approvals would drive this global atrial fibrillation market growth. For instance, in April 2024, the American Heart Association (AHA) initiated a new program aimed at involving pharmacists in the management of patients with atrial fibrillation (AFib), a prevalent heart condition affecting millions. This initiative is part of the AHA's broader Four Fs of Atrial Fibrillation campaign, which seeks to address specific patient health concerns that can impede effective anticoagulant therapy.

Also, in February 2023, Abbott announced two significant regulatory approvals as part of its expanding range of electrophysiology products in the global market. The TactiFlex Ablation Catheter, Sensor Enabled, recognized as the world's only ablation catheter with a flexible tip and contact force sensing technology, has received the CE Mark for use in treating patients with abnormal heart rhythms, including atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as a dominant force in the global atrial fibrillation market.

Asia Pacific is growing at the fastest pace in the global atrial fibrillation market share

Asia Pacific holds the fastest pace in the global atrial fibrillation market and is expected to hold most of the market share, fuelled by various factors that reflect the increasing prevalence of this condition and advancements in healthcare. Currently, more than 16 million people in the Asia Pacific region are affected by atrial fibrillation, with projections indicating this number could rise to 72 million by 2050. This escalating prevalence underscores the urgent need for effective treatment options.

The rising incidence of atrial fibrillation is a primary driver of market growth. The significant increase in AFib cases necessitates enhanced diagnostic and treatment options across the region. The aging demographic in Asia Pacific countries, particularly in nations like China and India, significantly contributes to the higher prevalence of AFib. As older adults are at a greater risk for cardiovascular diseases, this trend leads to increased demand for AFib treatments.

Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options for AFib patients. These advancements not only improve patient outcomes but also increase the preference for minimally invasive procedures. Increased healthcare spending in many Asia Pacific countries supports the adoption of advanced treatment options for AFib. This financial commitment allows for better access to medications, devices, and specialized care facilities.

Furthermore, key player's strategies such as partnerships & collaborations and innovative product launches & approvals would drive this global atrial fibrillation market growth. For instance, in May 2024, OMRON Healthcare India partnered with AliveCor India, a leader in personal electrocardiogram (ECG) technology, to enhance its cardiovascular health monitoring solutions, particularly focusing on atrial fibrillation (AFib). This collaboration is significant as it allows OMRON, which is primarily known for its blood pressure monitoring devices, to expand into the realm of AI-based handheld ECG technology.

Also, in May 2024, Medtronic announced that its PulseSelect pulsed field ablation (PFA) system has received regulatory approval in Japan, significantly expanding the availability of this innovative technology for treating patients with paroxysmal and persistent atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as the fastest-growing force in the global atrial fibrillation market.

Competitive Landscape

The major global players in the atrial fibrillation market include AdvaCare Pharma, Sanofi, Pfizer Inc. Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., GSK plc., Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, DAIICHI SANKYO COMPANY, LIMITED., AstraZeneca, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and Abbott. among others.

Key Developments

  • In November 2024, Johnson & Johnson MedTech announced that the U.S. Food and Drug Administration (FDA) has approved its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib). This approval signifies a major advancement in cardiac arrhythmia treatment, particularly for patients who do not respond to standard drug therapies.
  • In May 2024, Saint Luke's Mid-America Heart Institute launched a comprehensive digital health program in partnership with Story Health to support patients diagnosed with atrial fibrillation (AFib) or those at risk of developing the condition. This initiative aims to enhance patient care by providing continuous support and engagement beyond traditional clinic visits.
  • In March 2024, Asheville's Mission Hospital announced that it is the first facility in North Carolina to implement a new ablation strategy for treating atrial fibrillation (AFib), the most common type of arrhythmia, which affects approximately seven million Americans. This innovative procedure utilizes the FARAPULSE PFA System, a state-of-the-art technology that enhances both the safety and effectiveness of AFib treatment.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global atrial fibrillation market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End-User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advances in Medical Technology
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Pharmacological Treatment*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Anti-arrhythmic Drugs
    • 6.2.4. Amiodarone
    • 6.2.5. Dronedarone
    • 6.2.6. Dofetilide
    • 6.2.7. Sotalol
    • 6.2.8. Flecainide
    • 6.2.9. Propafenone
    • 6.2.10. Digoxin
    • 6.2.11. Anticoagulant Drugs
    • 6.2.12. Warfarin
    • 6.2.13. Dabigatran
    • 6.2.14. Rivaroxaban
    • 6.2.15. Apixaban
    • 6.2.16. Edoxaban
    • 6.2.17. Non-Dihydropyridine Calcium Channel Blockers
    • 6.2.18. Diltiazem
    • 6.2.19. Verapamil
    • 6.2.20. Beta-Blockers
    • 6.2.21. Metoprolol
    • 6.2.22. Carvedilol
  • 6.3. Others
  • 6.4. Non-Pharmacological Treatment
    • 6.4.1. Catheter Ablation
    • 6.4.2. Maze Surgery
    • 6.4.3. Electric Cardioversion
    • 6.4.4. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals & Specialty Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Spain
      • 8.3.5.5. Italy
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. South Korea
      • 8.5.5.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 10.1. AdvaCare Pharma*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Sanofi
  • 10.3. Pfizer Inc.
  • 10.4. Teva Pharmaceuticals USA, Inc.
  • 10.5. Glenmark Pharmaceuticals Inc.
  • 10.6. GSK plc.
  • 10.7. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.8. Bayer AG
  • 10.9. DAIICHI SANKYO COMPANY, LIMITED.
  • 10.10. AstraZeneca
  • 10.11. Johnson & Johnson
  • 10.12. Boston Scientific Corporation
  • 10.13. Medtronic
  • 10.14. Abbott.

LIST NOT EXHAUSTIVE

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us